Retirement Planning CO Of New England, Inc. Inhibikase Therapeutics, Inc. Transaction History

Retirement Planning CO Of New England, Inc.

$197 Million
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 21, 2023	SELL	$0.54 - $0.91 $168 - $283	-312 Reduced 0.89%	34,900 $23,000
Q4 2022 Feb 03, 2023	SELL	$0.45 - $5.41 $10,735 - $129,066	-23,857 Reduced 40.39%	35,212 $17,000
Q3 2022 Oct 19, 2022	SELL	$0.76 - $5.46 $4,208 - $30,232	-5,537 Reduced 8.57%	59,069 $53,000
Q2 2022 Aug 12, 2022	SELL	$0.63 - $1.44 $32,631 - $74,586	-51,796 Reduced 44.5%	64,606 $47,000
Q1 2022 May 06, 2022	SELL	$1.03 - $1.77 $31,856 - $54,744	-30,929 Reduced 20.99%	116,402 $172,000
Q4 2021 Feb 08, 2022	BUY	$1.38 - $2.17 $203,316 - $319,708	147,331 New	147,331 $216,000

Others Institutions Holding IKT

# of Institutions

Shares Held

1.03M

Call Options Held

Put Options Held

Act Capital Management, LLC Wayne, PA

938K
Shares

$2.94 Million
1.18% of portfolio
Zeke Capital Advisors, LLC Berwyn, PA

93.8K
Shares

$294,532
0.0% of portfolio

View Full List

About Inhibikase Therapeutics, Inc.

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $79.2M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

More about IKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Retirement Planning CO Of New England, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Retirement Planning CO Of New England, Inc. with notifications on news.

Account